Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.51 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | ROR1 | Q01973 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15443267 | 0.94 | ABL1 (0.51) | ABL1DDR1CSF1RROR1 | |
| SCHEMBL16644546 | 0.83 | ABL1 (0.53) | ABL1DDR1CSF1RROR1 | |
| SCHEMBL20144337 | 0.75 | NPBWR1 (0.44) | — | |
| SCHEMBL15443243 | 0.73 | ABL1 (0.58) | ABL1DDR1CSF1R | |
| SCHEMBL15445593 | 0.73 | MAOA (0.41) | — | |
| SCHEMBL25649582 | 0.69 | ABL1 (0.56) | ABL1DDR1CSF1RROR1 | |
| SCHEMBL14705592 | 0.68 | CSF1R (0.55) | ABL1DDR1CSF1RROR1 | |
| SCHEMBL17471717 | 0.68 | CSF1R (0.57) | ABL1CSF1RROR1 | |
| SCHEMBL16283150 | 0.67 | NPC1 (0.44) | — | |
| SCHEMBL16644581 | 0.67 | ABL1 (1.00) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3186247-B1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-2880038-B1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9174996-B2 | Protein kinase inhibitors | ASTAR BIOTECH LLC (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140364436-A1 | Protein Kinase Inhibitors | ASTAR BIOTECH LLC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8859553-B2 | Protein kinase inhibitors | ASTAR BIOTECH LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20140031354-A1 | Protein Kinase Inhibitors | ASTAR BIOTECH LLC (US) | 2014-01-30 | — | — | US | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | IFNAR1, IFNG, IRF3 | ABL1 566/4885DDR1 4558/4885CSF1R 2852/4885 |
| US-20140364436-A1 | Protein Kinase Inhibitors | MAP3K9, MAP3K6, MAP3K8 | ABL1 171/4885DDR1 1861/4885CSF1R 2152/4885 |
| US-20140031354-A1 | Protein Kinase Inhibitors | MAP3K1, MAP3K5, MAP3K7 | ABL1 134/4885DDR1 1414/4885CSF1R 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.